Creatine + HMB for Active Older Adults: What This 21-Week Crossover Trial Found About Mobility and Metabolism
Summary
If you're over 60 and already exercising regularly, you might assume you've "done enough" to stay mobile and independent. A new randomized, double-blind, placebo-controlled crossover trial (published January 2026 in Aging Clinical and Experimental Research) suggests that pairing two inexpensive, widely available supplements — creatine monohydrate and β-hydroxy-β-methylbutyrate (HMB) — with structured exercise can push functional performance even further.
Researchers in Tenerife, Spain, recruited 30 physically active adults aged 60–82 (20 men, 10 women) who were already meeting activity guidelines (≥150 min/week of moderate exercise). Using a crossover design — where every participant cycled through both conditions — each person did two 6-week blocks of a supervised, 4-day-a-week multicomponent exercise program (strength, power, circuits, HIIT, and steady-state cardio). During one block they took 3 g/day creatine monohydrate plus 3 g/day HMB (dissolved in yogurt or juice before bed); during the other, an identical-looking inulin placebo. A 3-week washout separated the two phases, and neither participants nor assessors knew which supplement was which.
The headline results: compared with placebo, the creatine+HMB phase produced significantly larger improvements in four core "mobility vital signs" — 4-meter gait speed, the 5-times sit-to-stand test, Timed Up and Go, and the 400-meter walk (all p<0.05, with large effect sizes, partial η² up to 0.42). These are the same measures geriatricians use to flag frailty risk and predict falls, hospitalization, and loss of independence — so the size of the effect here is clinically, not just statistically, notable. The placebo-plus-exercise phase, by contrast, showed no significant within-phase improvement on these tests, suggesting the supplement combo added something beyond the training program alone.
Beyond mobility, basal metabolic rate (BMR) and a "metabolic rate index" rose more with creatine+HMB, and visceral fat trended lower (though not statistically significant). Effects diverged somewhat by sex: women saw a modest (<5 mmHg) reduction in diastolic blood pressure and greater gains in expiratory muscle strength, while men showed a small, transient rise in a vascular marker called EPCR — interpreted by the authors as adaptive rather than harmful, since it wasn't paired with blood pressure or inflammation increases. Notably, a composite score (SPPB) didn't budge, likely because these already-active participants scored near the test's maximum at baseline — a ceiling effect rather than a true lack of benefit. This builds on the same team's earlier 2025 trial in the same population, which found creatine+HMB improved strength endurance independent of muscle mass — together painting a consistent picture that this combo may sharpen "muscle quality" and functional efficiency even without visible size gains.
What This Means For You
For supplement shoppers, the protocol here is simple and matches mainstream sports-nutrition guidance: 3 g/day creatine monohydrate (no loading phase needed) plus 3 g/day HMB (as calcium HMB), taken together once daily — the study used bedtime dosing dissolved in yogurt or juice, which may help gastrointestinal tolerance. Creatine monohydrate is the cheapest, most-studied form; look for third-party-tested products (e.g., Informed Sport/NSF Certified for Sport) since supplements aren't FDA-verified for purity. HMB is sold as HMB-Ca or the more bioavailable HMB-FA; the 3 g/day dose used here matches the amount most consistently linked to reduced muscle protein breakdown in prior research.
The key caveat: supplements alone weren't tested. Every participant, in both phases, did 4 supervised 60-minute sessions/week combining strength, power, balance, and cardio work. The exercise is almost certainly doing the heavy lifting — the supplements appear to amplify it, not replace it. So the practical takeaway isn't "take creatine and skip the gym," it's "if you're already training consistently, this stack may extract more functional gain from that same effort."
Who benefits most? Physically active, independent older adults looking to preserve gait speed, chair-rising ability, and walking endurance — all strong predictors of fall risk and independence. The ISSN reaffirmed in 2025 that creatine is safe across the lifespan at doses well above 3 g/day, and no renal symptoms or serious adverse events emerged here (though formal kidney function testing wasn't done). People with kidney disease, uncontrolled chronic conditions, or those on blood thinners (given the EPCR/coagulation signal in men) should check with a doctor before starting. Cost is modest — both ingredients are inexpensive, widely available commodities — making this a low-risk, low-cost adjunct to consider alongside, not instead of, consistent multicomponent training.
Important Considerations
This was a small trial (30 completers, only 10 women) over just six weeks per phase — far shorter than the years-long timelines over which real-world sarcopenia and mobility decline unfold. We don't know whether benefits persist after stopping supplementation, or whether starting sooner versus later in aging matters. Participants were already physically active and had high baseline functional scores (hence the ceiling effect on the SPPB test) — results may not generalize to frail, sedentary, or institutionalized older adults, which the authors explicitly flag as a direction for future research (a related "MULTI-FRAIL" trial is reportedly already underway in that population).
Body composition and BMR were measured with bioelectrical impedance (a home-scale-type technology), not gold-standard DEXA scans or indirect calorimetry, so absolute numbers should be taken as estimates, not precise values. The dose (3 g/day each) wasn't adjusted for body weight, which may explain some of the sex differences seen. Critically, this trial tested creatine and HMB together — there's no arm testing either supplement alone, so it can't tell you whether one ingredient is doing most of the work or whether they're truly synergistic. Adherence was tracked by sachet counts and logs, not blood tests, so actual compliance is somewhat assumed rather than verified.
Red flag for marketing: don't expect visible muscle bulk from this stack — the companion trial from this group found strength gains occurred independent of muscle mass changes, so "get bigger muscles" claims aren't supported here. As with any supplement study, consult a physician before starting, especially if you have kidney, liver, or cardiovascular conditions, or take medications affecting blood clotting.
Terms Explained
Technical Study Details
Study Design
Total Score
JADAD Quality Assessment評価詳細
Randomization
2 / 2Blinding
2 / 2Dropouts/Withdrawals
1 / 1Study Population
- Age ≥ 60 years
- Physical independence
- Engagement in ≥ 150 min/week of moderate-intensity physical activity
Interventions
Creatine monohydrate (CRE)
Treatmentβ-Hydroxy-β-methylbutyrate (HMB, as calcium HMB/HMB-Ca)
TreatmentPlacebo (Inulin)
ControlIntegral Physical Conditioning (IPC) multicomponent exercise program
TreatmentOutcomes
| Outcome | Type | Effect | p-value |
|---|---|---|---|
| 4-m Gait Speed | Primary | - | p < 0.001 (interaction); p < 0.05 (POST between-group)Significant |
| 5-Repetition Sit-to-Stand (5R-STS) | Primary | - | p < 0.001 (interaction); p < 0.05 (POST between-group)Significant |
| Timed Up and Go (TUG) | Primary | - | p < 0.001 (interaction); p < 0.05 (POST between-group)Significant |
| 400-Meter Walk Test | Primary | - | p < 0.001 (interaction); p < 0.05 (POST between-group)Significant |
| Short Physical Performance Battery (SPPB) total score | Secondary | - | - |
| Static Balance (SPPB subtest) | Secondary | - | - |
| Basal Metabolic Rate (BMR) | Secondary | - | p < 0.001Significant |
| Visceral Fat Index | Secondary | - | - |
| Metabolic Rate Index | Secondary | - | p = 0.026Significant |
| Metabolic Age | Secondary | - | - |
| Systolic Blood Pressure (SBP) | Secondary | - | - |
| Diastolic Blood Pressure (DBP) | Secondary | - | p = 0.020 (interaction, women); p = 0.015 (DBP reduction, women)Significant |
| Resting Heart Rate | Secondary | - | - |
| Peripheral Oxygen Saturation (SpO2) | Secondary | - | - |
| Maximal Expiratory Pressure (MEP) | Secondary | - | -Significant |
| Endothelial Protein C Receptor (EPCR) | Secondary | - | p = 0.021 (men); p = 0.920 (total sample, not significant)Significant |
Safety
Conclusion
Six weeks of combined creatine monohydrate and HMB supplementation, integrated with a supervised multicomponent exercise program (IPC), produced meaningful improvements in functional performance (4-m gait speed, 5R-STS, TUG, 400-m walk), metabolic efficiency (BMR, metabolic rate index), and selected physiological outcomes (MEP, and sex-specific DBP and EPCR changes) in physically active older adults, with large effect sizes and no significant period, sequence, or carryover effects. CRE + HMB supplementation combined with exercise appears to be a safe, feasible, and practical strategy to sustain mobility, metabolic health, and functional independence with aging, though findings should be confirmed in longer trials and in frail or sedentary populations.Limitations
- Short intervention period (six weeks) limits assessment of persistence of benefits or long-term adaptations after cessation.
- Body composition and BMR were estimated using multifrequency bioelectrical impedance analysis rather than gold-standard methods (DXA or indirect calorimetry), reducing precision of absolute values.
- Fixed dosing strategy (3 g/day CRE and 3 g/day HMB) was not normalized to body mass, potentially contributing to interindividual and sex-specific variability.
- No biochemical verification of supplement adherence was performed (relied on sachet counts, logs, and supervision).
- No single-supplement comparison arms (CRE-only or HMB-only) were included, precluding evaluation of additive versus synergistic effects.
- No statistical adjustment for sex-related differences in fat-free mass was applied, to avoid model overfitting given the modest sample size.
- Sex-specific analyses were exploratory; the study was not powered a priori to formally test sex-by-intervention interactions.
- Confidence intervals were not systematically reported for all effect size estimates, limiting precision of interpretation.
- High baseline functional status of participants likely produced a ceiling effect limiting the sensitivity of the SPPB to detect further improvement.
- Training-induced baseline improvement across phases may have attenuated some between-condition contrasts.